241 related articles for article (PubMed ID: 25363835)
1. AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation.
Feuerbach D; Pezous N; Weiss M; Shakeri-Nejad K; Lingenhoehl K; Hoyer D; Hurth K; Bilbe G; Pryce CR; McAllister K; Chaperon F; Kucher K; Johns D; Blaettler T; Lopez Lopez C
Br J Pharmacol; 2015 Mar; 172(5):1292-304. PubMed ID: 25363835
[TBL] [Abstract][Full Text] [Related]
2. Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: A randomized trial.
Barch DM; Marder SR; Harms MP; Jarskog LF; Buchanan RW; Cronenwett W; Chen LS; Weiss M; Maguire RP; Pezous N; Feuerbach D; Lopez-Lopez C; Johns DR; Behrje RB; Gomez-Mancilla B
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Nov; 71():66-75. PubMed ID: 27371157
[TBL] [Abstract][Full Text] [Related]
3. A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.
Trenkwalder C; Berg D; Rascol O; Eggert K; Ceballos-Baumann A; Corvol JC; Storch A; Zhang L; Azulay JP; Broussolle E; Defebvre L; Geny C; Gostkowski M; Stocchi F; Tranchant C; Derkinderen P; Durif F; Espay AJ; Feigin A; Houeto JL; Schwarz J; Di Paolo T; Feuerbach D; Hockey HU; Jaeger J; Jakab A; Johns D; Linazasoro G; Maruff P; Rozenberg I; Sovago J; Weiss M; Gomez-Mancilla B
Mov Disord; 2016 Jul; 31(7):1049-54. PubMed ID: 26990766
[TBL] [Abstract][Full Text] [Related]
4. The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents.
Boess FG; De Vry J; Erb C; Flessner T; Hendrix M; Luithle J; Methfessel C; Riedl B; Schnizler K; van der Staay FJ; van Kampen M; Wiese WB; Koenig G
J Pharmacol Exp Ther; 2007 May; 321(2):716-25. PubMed ID: 17308038
[TBL] [Abstract][Full Text] [Related]
5. EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors.
Prickaerts J; van Goethem NP; Chesworth R; Shapiro G; Boess FG; Methfessel C; Reneerkens OA; Flood DG; Hilt D; Gawryl M; Bertrand S; Bertrand D; König G
Neuropharmacology; 2012 Feb; 62(2):1099-110. PubMed ID: 22085888
[TBL] [Abstract][Full Text] [Related]
6. AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.
Di Paolo T; Grégoire L; Feuerbach D; Elbast W; Weiss M; Gomez-Mancilla B
Parkinsonism Relat Disord; 2014 Nov; 20(11):1119-23. PubMed ID: 25172125
[TBL] [Abstract][Full Text] [Related]
7. Effects of BMS-902483, an α7 nicotinic acetylcholine receptor partial agonist, on cognition and sensory gating in relation to receptor occupancy in rodents.
Pieschl RL; Miller R; Jones KM; Post-Munson DJ; Chen P; Newberry K; Benitex Y; Molski T; Morgan D; McDonald IM; Macor JE; Olson RE; Asaka Y; Digavalli S; Easton A; Herrington J; Westphal RS; Lodge NJ; Zaczek R; Bristow LJ; Li YW
Eur J Pharmacol; 2017 Jul; 807():1-11. PubMed ID: 28438647
[TBL] [Abstract][Full Text] [Related]
8. In vitro binding characteristics of [3H]AZ11637326, a novel alpha7-selective neuronal nicotinic receptor agonist radioligand.
Gordon JC; Phillips E; Gurley DA; Heys JR; Lazor LA; Barthlow HG; Mallamaci MA; Keith RA
Eur J Pharmacol; 2010 Oct; 645(1-3):63-9. PubMed ID: 20674564
[TBL] [Abstract][Full Text] [Related]
9. Cognitive improvements in a mouse model with substituted 1,2,3-triazole agonists for nicotinic acetylcholine receptors.
Arunrungvichian K; Boonyarat C; Fokin VV; Taylor P; Vajragupta O
ACS Chem Neurosci; 2015 Aug; 6(8):1331-40. PubMed ID: 25978789
[TBL] [Abstract][Full Text] [Related]
10. Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity.
Acker BA; Jacobsen EJ; Rogers BN; Wishka DG; Reitz SC; Piotrowski DW; Myers JK; Wolfe ML; Groppi VE; Thornburgh BA; Tinholt PM; Walters RR; Olson BA; Fitzgerald L; Staton BA; Raub TJ; Krause M; Li KS; Hoffmann WE; Hajos M; Hurst RS; Walker DP
Bioorg Med Chem Lett; 2008 Jun; 18(12):3611-5. PubMed ID: 18490160
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological and behavioral profile of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide (EVP-5141), a novel α7 nicotinic acetylcholine receptor agonist/serotonin 5-HT3 receptor antagonist.
Boess FG; de Vry J; Erb C; Flessner T; Hendrix M; Luithle J; Methfessel C; Schnizler K; van der Staay FJ; van Kampen M; Wiese WB; König G
Psychopharmacology (Berl); 2013 May; 227(1):1-17. PubMed ID: 23241647
[TBL] [Abstract][Full Text] [Related]
12. Concentration-response relationship of the α7 nicotinic acetylcholine receptor agonist FRM-17874 across multiple in vitro and in vivo assays.
Stoiljkovic M; Leventhal L; Chen A; Chen T; Driscoll R; Flood D; Hodgdon H; Hurst R; Nagy D; Piser T; Tang C; Townsend M; Tu Z; Bertrand D; Koenig G; Hajós M
Biochem Pharmacol; 2015 Oct; 97(4):576-589. PubMed ID: 26206187
[TBL] [Abstract][Full Text] [Related]
13. Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship.
Wishka DG; Walker DP; Yates KM; Reitz SC; Jia S; Myers JK; Olson KL; Jacobsen EJ; Wolfe ML; Groppi VE; Hanchar AJ; Thornburgh BA; Cortes-Burgos LA; Wong EH; Staton BA; Raub TJ; Higdon NR; Wall TM; Hurst RS; Walters RR; Hoffmann WE; Hajos M; Franklin S; Carey G; Gold LH; Cook KK; Sands SB; Zhao SX; Soglia JR; Kalgutkar AS; Arneric SP; Rogers BN
J Med Chem; 2006 Jul; 49(14):4425-36. PubMed ID: 16821801
[TBL] [Abstract][Full Text] [Related]
14. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia.
Pichat P; Bergis OE; Terranova JP; Urani A; Duarte C; Santucci V; Gueudet C; Voltz C; Steinberg R; Stemmelin J; Oury-Donat F; Avenet P; Griebel G; Scatton B
Neuropsychopharmacology; 2007 Jan; 32(1):17-34. PubMed ID: 16936709
[TBL] [Abstract][Full Text] [Related]
15. In vivo and in vitro ADMET profiling and in vivo pharmacodynamic investigations of a selective α7 nicotinic acetylcholine receptor agonist with a spirocyclic Δ
Matera C; Dondio G; Braida D; Ponzoni L; De Amici M; Sala M; Dallanoce C
Eur J Pharmacol; 2018 Feb; 820():265-273. PubMed ID: 29275158
[TBL] [Abstract][Full Text] [Related]
16. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.
Bitner RS; Bunnelle WH; Decker MW; Drescher KU; Kohlhaas KL; Markosyan S; Marsh KC; Nikkel AL; Browman K; Radek R; Anderson DJ; Buccafusco J; Gopalakrishnan M
J Pharmacol Exp Ther; 2010 Sep; 334(3):875-86. PubMed ID: 20504913
[TBL] [Abstract][Full Text] [Related]
17. Role of channel activation in cognitive enhancement mediated by alpha7 nicotinic acetylcholine receptors.
Briggs CA; Grønlien JH; Curzon P; Timmermann DB; Ween H; Thorin-Hagene K; Kerr P; Anderson DJ; Malysz J; Dyhring T; Olsen GM; Peters D; Bunnelle WH; Gopalakrishnan M
Br J Pharmacol; 2009 Nov; 158(6):1486-94. PubMed ID: 19845675
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies.
Barbier AJ; Hilhorst M; Van Vliet A; Snyder P; Palfreyman MG; Gawryl M; Dgetluck N; Massaro M; Tiessen R; Timmerman W; Hilt DC
Clin Ther; 2015 Feb; 37(2):311-24. PubMed ID: 25438724
[TBL] [Abstract][Full Text] [Related]
19. Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).
Ghiron C; Haydar SN; Aschmies S; Bothmann H; Castaldo C; Cocconcelli G; Comery TA; Di L; Dunlop J; Lock T; Kramer A; Kowal D; Jow F; Grauer S; Harrison B; La Rosa S; Maccari L; Marquis KL; Micco I; Nencini A; Quinn J; Robichaud AJ; Roncarati R; Scali C; Terstappen GC; Turlizzi E; Valacchi M; Varrone M; Zanaletti R; Zanelli U
J Med Chem; 2010 Jun; 53(11):4379-89. PubMed ID: 20465311
[TBL] [Abstract][Full Text] [Related]
20. The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia.
Bristow LJ; Easton AE; Li YW; Sivarao DV; Lidge R; Jones KM; Post-Munson D; Daly C; Lodge NJ; Gallagher L; Molski T; Pieschl R; Chen P; Hendricson A; Westphal R; Cook J; Iwuagwu C; Morgan D; Benitex Y; King D; Macor JE; Zaczek R; Olson R
PLoS One; 2016; 11(7):e0159996. PubMed ID: 27467081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
